UBS Group
RANI icon

UBS Group’s Rani Therapeutics RANI Stock Holding History

UBS Group’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$167K Buy
227,223
+75,700
+50% +$96.7K ﹤0.01% 6733
2025
Q4 		$205K Buy
151,523
+82,400
+119% +$124K ﹤0.01% 6565
2025
Q3 		$34.6K Buy
69,123
+7,059
+11% +$3.68K ﹤0.01% 7807
2025
Q2 		$31.9K Sell
62,064
-10,053
-14% -$8.2K ﹤0.01% 8117
2025
Q1 		$90.9K Buy
72,117
+48,592
+207% +$71.9K ﹤0.01% 7117
2024
Q4 		$32.2K Buy
23,525
+7,816
+50% +$16.4K ﹤0.01% 7555
2024
Q3 		$33.9K Buy
15,709
+12,709
+424% +$36.4K ﹤0.01% 7061
2024
Q2 		$11.4K Hold
3,000
– – ﹤0.01% 7644
2024
Q1 		$9.33K Buy
+3,000
New +$10.3K ﹤0.01% 7289
2023
Q4 		– Sell
-5,700
Closed -$12.4K – 9782
2023
Q3 		$12.4K Buy
5,700
+1,688
+42% +$6.45K ﹤0.01% 7021
2023
Q2 		$16.5K Buy
4,012
+3,012
+301% +$14K ﹤0.01% 6959
2023
Q1 		$5.16K Hold
1,000
– – ﹤0.01% 8076
2022
Q4 		$5.9K Hold
1,000
– – ﹤0.01% 9118
2022
Q3 		$10K Sell
1,000
-1,538
-61% -$16.3K ﹤0.01% 8451
2022
Q2 		$26K Sell
2,538
-1,032
-29% -$11.8K ﹤0.01% 6561
2022
Q1 		$48K Sell
3,570
-1,621
-31% -$26.9K ﹤0.01% 6537
2021
Q4 		$85K Buy
5,191
+2,121
+69% +$48.2K ﹤0.01% 6459
2021
Q3 		$55K Buy
+3,070
New +$53.1K ﹤0.01% 6265

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

UBS Group's RANI Position: Q1 2026 in Review

UBS Group increased its Rani Therapeutics (RANI) stake by 50% in Q1 2026, buying an estimated $96.7K and bringing the position to 227,223 shares worth $167K. The position accounts for ﹤0.01% of the portfolio, ranked #6733.

UBS Group first reported a position in RANI in Q3 2021 and has held it in 18 quarters since. The position peaked at $205K in Q4 2025. 74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

  • UBS Group held 227,223 shares of Rani Therapeutics worth $167K as of Q1 2026.
  • UBS Group bought 75,700 Rani Therapeutics shares in Q1 2026, an estimated $96.7K.
  • Rani Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6733 holding.
  • UBS Group first reported a position in Rani Therapeutics in Q3 2021 and has held it in 18 quarters since.
  • UBS Group's Rani Therapeutics position peaked at $205K in Q4 2025.
  • 74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.